At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 168 enrolled
Drug / intervention
Valsartan 160mg +3 moredrug
Likely dose
Valsartan 160mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Factorial, Double-blinded, Double-dummy Phase Ⅲ Trial to Evaluate the Efficacy and Safety of the Coadministration of Valsartan 160mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone in Patients With Hypertension and Hyperlipidemia
In Brief
A Phase 3 clinical trial evaluating Valsartan 160mg, Rosuvastatin 20mg, and 2 other interventions for Hypertension, and Hyperlipidemia. Completed, enrolled 168 participants across 1 site.
Detailed Summary
This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and hyperlipidemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension,, Hyperlipidemia
CountriesSouth Korea
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
Primary CompletionMar 2013
First PostedAug 2013
TodayJul 2026
First PostedAug 7, 2013
Enrollment StartApr 1, 2012
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.9 years ago
Interventions
Valsartan 160mgdrug
Rosuvastatin 20mgdrug
Valsartan 160mg placebodrug
Rosuvastatin 20mg placebodrug